Brain biocompatibility of a biodegradable controlled release polymer consisting of anhydride copolymer of fatty acid dimer and sebacic acid

Polyanhydrides

“…Fatty acid dimer -based polymers have been thoroughly investigated for their biocompatibility. Brem et al also studied the in vivo biocompatibility of P(FAD -SA) 50:50 in rat brain [30] . All animals survived to the scheduled date of sacrifi ce with no evidence of behavioral changes or neurological defi cits suggestive of toxicity.…”

The brain tissue response to biodegradable poly(methylidene malonate 2.1.2)-based microspheres in the rat

“…Before testing the therapeutic efficacy of a drug delivery device in clinical trials, researchers must first control the safety of the polymeric material and of its degradation products, in a convenient way [10]. Controlled release systems implanted in humans were tested before use in several biocompatibility studies performed in vivo in appropriate animal models [11][12][13][14][15][16].…”

Chemotherapy for high-grade gliomas

“…Two polyanhydride systems have been studied extensively; p(CPP-SA) for hydrophobic drugs such as BCNU; p(FAP-SA) for hydrophilic compounds, and those susceptible to hydrolysis such as methotrexate and cisplatin (Brem et al, 1992;Domb et al, 1991). Brem et al (1992) have established the safety of this methodology.…”

“…Two polyanhydride systems have been studied extensively; p(CPP-SA) for hydrophobic drugs such as BCNU; p(FAP-SA) for hydrophilic compounds, and those susceptible to hydrolysis such as methotrexate and cisplatin (Brem et al, 1992;Domb et al, 1991). Brem et al (1992) have established the safety of this methodology. In a recent randomized placebo-controlled trial of 222 patients with recurrent gliomas, 6-month survival was greater in glioblastoma patients treated with BCNU wafers than in the placebo group (64% vs 44%) (Brem et al, 1995).…”